Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous DC-CTL/TIL for Breast Cancer Prevention and Treatment
ChiCTR-IIR-17011292Phase 2Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jul 2017
- Modality
- Adoptive Cell Transfer → Cell Therapies, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous DC-CTL and autologous tumor-infiltrating lymphocytes in breast cancer (2 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoints: Incidence of breast cancer and Progression-free survival. Planned start Jul 2017; status: not yet recruiting.
02
Drugs
autologous DC-CTLautologous tumor-infiltrating lymphocytes
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-IIR-17011292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17011292.